U.S. pharma large copyright scrapped two experimental weight loss capsules last calendar year—a after-daily tablet, lotiglipron, due to elevated liver enzymes along with a two times-day-to-day tablet, danuglipron, as a result of strong Unintended effects—but CEO Albert Bourla has claimed the company is set to “Enjoy and win” from the being